CR

CRISM Therapeutics Corporation

Develops drug delivery technology for localized chemotherapy in solid tumors.

CRTX | US

Overview

Corporate Details

ISIN(s):
VGG042401262
LEI:
213800XFW6MKVCHHPW88
Country:
Virgin Islands (British)
Address:
C/O MAPLES FINANCE BVI LIMITED, VG1110 ROAD TOWN

Description

CRISM Therapeutics Corporation is a pharmaceutical company focused on developing advanced drug delivery technologies. Its flagship product, ChemoSeed®, is an implantable, biodegradable technology designed for the sustained and localized delivery of chemotherapy drugs directly into solid tumors. The primary objective of this approach is to enhance the efficacy of cancer treatments by concentrating therapeutic agents at the tumor site, thereby minimizing systemic toxicity and associated side effects. The company's technology aims to improve the clinical performance of cancer therapies and the bioavailability of poorly soluble compounds, with a mission to provide more effective and better-tolerated treatments to improve patient quality of life.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2019-03-01 14:37
PFS Executive Summary
English 13.7 KB
2019-02-27 09:58
Conversion of Loan and Issue of Equity
English 15.0 KB
2019-02-26 08:00
Kun-Manie Pre-Feasibility Study
English 46.9 KB
2019-02-22 10:42
Access Road Capital Cost Update
English 22.8 KB
2019-02-21 10:47
Directors Dealing
English 31.6 KB
2019-02-06 08:00
2018 Alex Stewart Laboratory Final Results
English 197.5 KB
2019-01-22 13:01
Directors Dealing
English 31.5 KB
2019-01-02 11:20
Conversion of Loan and Issue of Equity
English 15.0 KB
2018-12-24 11:12
Conversion of Loan and Issue of Equity
English 15.0 KB
2018-12-21 10:06
Directors Dealing
English 31.6 KB
2018-12-13 11:15
Annual General Meeting Results
English 16.9 KB
2018-11-28 13:26
Notice of Annual General Meeting
English 13.9 KB
2018-11-28 11:54
Conversion of Loan and Issue of Equity
English 15.0 KB
2018-11-20 11:28
Directors Dealing
English 31.6 KB
2018-11-19 16:05
Investor Event
English 13.9 KB

Automate Your Workflow. Get a real-time feed of all CRISM Therapeutics Corporation filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CRISM Therapeutics Corporation

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CRISM Therapeutics Corporation via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.